PRMT4 inhibitor / BMS, Ipsen - LARVOL DELTA

THE ARGININE METHYLTRANSFERASE CARM1 AS A NOVEL POTENTIAL THERAPEUTIC TARGET IN HEPATOCELLULAR CARCINOMA (AEEH 2026) - No abstract available

Hepatocellular Cancer • Oncology • Solid Tumor

Characterization of CARM1 Inhibition in Skeletal Muscle. (PubMed, FASEB J) - "Mice were treated with either a CARM1 inhibitor (150 mg/kg EZM2302; Epizyme, Inc.) or vehicle via oral gavage BID for 2, 4, or 8 days. Furthermore, CARM1 inhibitor treatment may affect muscle performance with males being more sensitive to the functional outcomes of CARM1 suppression than females. Future work in our laboratory will examine the mechanisms and functional consequences of sex-based differences in CARM1 biology within skeletal muscle."

Journal • PABPC1